IP Library Granted Patent US 9,441,027
Granted Patent B2
US 9,441,027 · App. 14/791,047 · Granted Sep 13, 2016

Natriuretic polypeptides

Inventors: Candace Y.W. Lee (Dollard-des-Ormeaux, CA); John C. Burnett, Jr. (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
C07K14/58A61K38/00A61K38/1709A61K38/2242C07K7/08C07K14/47
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,441,027
App. No.
14/791,047
Granted
Sep 13, 2016
Kind
B2
Abstract

This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.

Claims (15)

1. A polypeptide from 24 to 55 amino acid residues in length, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:

(a) the sequence set forth in SEQ ID NO:1 or the sequence set forth in SEQ ID NO:1with no more than two additions, deletions, or substitutions,

(b) the sequence set forth in SEQ ID NO:3 or the sequence set forth in SEQ ID NO: 3 with no more than two additions, deletions, or substitutions, and

(c) the sequence set forth in SEQ ID NO:12 or the sequence set forth in SEQ ID NO: 12 with no more than two additions, deletions, or substitutions.

2. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:1 with two additions, deletions, or substitutions.

3. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:1 with one addition, deletion, or substitution.

4. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:1.

5. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:3 with two additions, deletions, or substitutions.

6. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:3 with one addition, deletion, or substitution.

7. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:3.

8. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:12 with two additions, deletions, or substitutions.

9. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:12 with one addition, deletion, or substitution.

10. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:12.

11. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:1, the sequence set forth in SEQ ID NO:3, and the sequence set forth in SEQ ID NO:12.

12. The polypeptide of claim 1 , wherein said polypeptide is as set forth in SEQ ID NO:60.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 23, 2016
From: MAYO CLINIC ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039127/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: LEE, CANDACE Y.W.; BURNETT, JOHN C., JR.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 036346/0622 →
Continuity (4)
Continuation 14003481
Provisional Application 61648718 · May 18, 2012
Provisional Application 61529113 · Aug 30, 2011
Related Publication 20150299284A1 · Oct 22, 2015